Voyager Therapeutics Inc VYGR
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-11-11 |
| Shares Out. | 60,420,000 |
| Website | voyagertherapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 141 |
| Revenue | $2.6M |
| Gross Profit | $2.6M |
| Net Income | -$27.9M |
| Free Cash Flow | -$129.9M |
| Total Assets | $219.3M |
| Total Liabilities | $45.7M |
| Equity | $173.7M |
About Voyager Therapeutics Inc
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Voyager Therapeutics Inc is a publicly traded company under the ticker symbol VYGR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)